# To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

> **NCT05356741** · PHASE1,PHASE2 · RECRUITING · sponsor: **Vir Biotechnology, Inc.** · enrollment: 645 (estimated)

## Conditions studied

- Locally Advanced or Metastatic HER2-Expressing Cancers

## Interventions

- **DRUG:** VIR-5818
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT05356741
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-13
- **Primary completion:** 2027-08-16
- **Final completion:** 2027-08-16
- **Target enrollment:** 645 (ESTIMATED)
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05356741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05356741, "To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05356741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*